Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
First-in-Class Oral Treatment for LN: Lupkynis (voclosporin) was the first FDA-approved oral calcineurin inhibitor specifically for the treatment of adult patients with active lupus nephritis, providing a novel and targeted therapy option.
Proven Clinical Efficacy: Pivotal clinical trials (AURORA 1 and 2) demonstrated superior renal response rates and a significant reduction in proteinuria compared to standard of care, establishing strong evidence of its therapeutic benefit.
Addresses Significant Unmet Medical Need: Lupus nephritis is a severe autoimmune disease with a high risk of kidney failure, and Lupkynis provides a much-needed, effective treatment option where existing therapies were often insufficient or associated with severe side effects.
Risks
Lupkynis Commercialization Risk: Failure to achieve anticipated sales and market penetration for their primary drug, Lupkynis, due to various factors including competition, physician adoption, or patient compliance.
Intense Competition Risk: The lupus nephritis market is competitive with other approved and pipeline therapies, which could limit Lupkynis's market share or pricing power.
Single Product Dependence Risk: Substantially all of Aurinia's revenue is derived from Lupkynis, making the company highly vulnerable to any issues impacting this single product's success or viability.
Over a week ago
Jun 4, 7:04 AM
Jun 3, 8:23 AM
May 7, 8:05 AM
May 7, 8:04 AM
Mar 23, 11:03 AM
Mar 23, 8:03 AM
Feb 26, 6:07 AM
Feb 26, 6:06 AM
Dec 3, 6:30 AM
Dec 3, 6:09 AM
Nov 7, 5:10 AM
Nov 4, 4:40 PM
Nov 4, 6:14 AM
Nov 4, 6:13 AM
Nov 3, 6:34 AM
Sep 30, 6:07 AM
Sep 29, 3:19 PM